Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3B | O95264 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9836913 | 0.85 | MAPK1 (0.52) | MAPK1TDP1HTR3EHTR3BHTR3A | |
| SCHEMBL11552930 | 0.85 | MAPK1 (0.52) | MAPK1TDP1HTR3EHTR3BHTR3A | |
| SCHEMBL5206535 | 0.83 | MAPK1 (0.59) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL7931082 | 0.81 | MAPK1 (0.57) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL14254774 | 0.81 | MAPK1 (0.57) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL8840231 | 0.81 | MAPK1 (0.57) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL11760689 | 0.78 | CYP3A4 (0.50) | MAPK1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL131042 | 0.78 | TDP1 (0.50) | MAPK1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL10648934 | 0.78 | MAPK1 (0.53) | MAPK1TDP1CYP3A4TSHRTRPA1 | |
| SCHEMBL93410 | 0.77 | MAPK1 (0.52) | MAPK1TDP1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2014163643-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014151719-A1 | SUBLINGUAL FORMULATIONS INCLUDING GERANYLGERANYLACETONE AND GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013130654-A1 | GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-1140735-A1 | PREPARATION OF NUCLEAR CHLORINATED AROMATIC COMPOUNDS | OCCIDENTAL CHEMICAL CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040524-A1 | PREPARATION OF NUCLEAR CHLORINATED AROMATIC COMPOUNDS | OCCIDENTAL CHEMICAL CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
| CN-1050124-C | Herbicide containing oxazolidinedione derivatives | SAGAMI CHEM RES (JP) | 2000-03-08 | — | — | CN | disclosed |
| US-5981789-A | CHLORODENITRATING AROMATIC COMPOUNDS USING LESS CHLORINATING AGENT AND LOWER TEMPERATURES, THEN RECYCLING THE PRODUCT MIXTURE TO INCREASE THE YIELD | OCCIDENTAL CHEMICAL CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0241559-B1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4983751-A | Chemical intermediates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0176868-B1 | BENZOYL UREAS HAVING AN INSECTICIDAL ACTIVITY | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-04-12 | — | — | EP | disclosed |
| US-4818272-A | NONPHYTOTOXICITY FOR CROPS HELICAL STREAMS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-04-04 | — | — | US | disclosed |
| US-4704483-A | FLUORINATION WITH POTASSIUM FLUORIDE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0241559-A1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1987-10-21 | — | — | EP | disclosed |
| CN-86108416-A | Oxazolidinedione derivative, process for producing the same, and herbicide containing the same | — | 1987-07-29 | — | — | CN | disclosed |
| US-4582948-A | VAPOR PHASE CHLORO-DENITRATION REACTION | OCCIDENTAL CHEMICAL CORPORATION (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0176868-A1 | Benzoyl ureas having an insecticidal activity | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-04-09 | — | — | EP | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | MAPK1 605/4885TDP1 1522/4885HTR3E 4494/4885 |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | MAPK1 605/4885TDP1 1522/4885HTR3E 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.